A european view-point on NSF

Current Rheumatology Reviews

Volumn 6, Issue 3, 2010, Pages 184-188

  Thomsen, Henrik S ^a,b   Morcos, Sameh K ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Gadolinium; Gadolinium based contrast agents; Nephrogenic systemic fibrosis; Stability; Very late adverse reactions

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM;

ARTICLE; CONTRAST ENHANCEMENT; HUMAN; KIDNEY FUNCTION; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; X-RAY COMPUTED TOMOGRAPHY;

EID: 80052724561     PISSN: 15733971     EISSN: 18756360     Source Type: Journal    
DOI: 10.2174/157339710791792757     Document Type: Article

References (44)

1. Grobner T. Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21: 1104-8.
2. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: Suspected etiological role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17: 2359-62.
3. Dawson P, Punwani S. Nephrogenic systemic fibrosis: non gadolinium options for the imaging of CKD/ESRD patients. Semin Dial 2008; 21: 160-5.
4. Lind RK, Thomsen HS. Nephrogenic systemic fibrosis and contrast medium-induced nephropathy: A choice between the devil and the deep blue sea for patients with reduced renal function? Acta Radiol 2009; 50: 965-7.
5. nd ed. Heidelberg: Springer 2009; pp. 229-42.
6. Morcos SK, Thomsen HS, Webb JAW, Members of the Contrast Media Safety Committee of European Society of Urogenital Radiology. Dialysis and contrast media. Eur Radiol 2002; 12: 3026-30.
7. Thomsen HS, Morcos SK, Barrett BJ. Contrast induced nephropathy: the wheel has turned 360 degrees. Acta Radiol 2008; 49: 646-57.
8. Solomon RJ, Mehran R, Natarjan MK, et al. Contrast-induced nephropathy and long-term advice events: Cause and Effect? Clin J Am Soc Nephrol 2009; 4: 1162-9.
9. Thomsen HS, Marckmann P, Logager VB. Update on nephrogenic systemic fibrosis. Magn Reson Imaging Clin N Am 2008; 16: 551-60.
10. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium(Gd)-containing magnetic resonance contrast agent. Invest Radiol 2008; 43: 65-75.
11. Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis. Predictor of early morality and association with gadolinium exposure. Arthritis Rheumatol 2007; 56: 3433-41.
12. Stenver DI. Pharmacovigilance: What to do if you see an adverse reaction and the consequences. Eur J Radiol 2008; 66: 184-8.
13. Wertman R, Altun E, Martin DR, et al. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 2008; 248: 799-806.
14. Morcos SK. Extracellular gadolinium contrast agents (Gd-CA): Differences in stability. Eur J Radiol 2008; 66: 175-9.
15. Thomsen HS, Marckmann P. Extracellular Gd-CA: Differences in prevalences of NSF. Eur J Radiol 2008: 66; 180-3.
16. Marckmann P, Skov L, Rossen K, Thomsen HS. Clinical manifestations of gadodiamide-related nephrogenic systemic fibrosis. Clin Nephrol 2008; 69: 161-8.
17. Singh M, Davenport A, Clatworthy I, et al. A follow-up of four cases of nephrogenic systemic fibrosis: is gadolinium the specific trigger? Br J Dermatol 2008; 158: 1358-62.
18. Collidge TA, Thomson PC, Mark PB, et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 2007; 245: 168-75.
19. Chrysochou C, Buckley DL, Dark P, Cowie A, Kalra PA. Gadolinium-enhanced magnetic resonance imaging for renovascular disease and nephrogenic systemic fibrosis: Critical review of the literature and UK experience. J Magn Reson Imaging 2009; 29: 887-94.
20. Abraham JL, Thakral C, Skov L, Rossen K, Marckann P. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 2007; 158: 273-80.
21. Abraham JL, Chandra S, Thakral C, Abraham JM. SIMS imaging og gadolinium isotopes in tissue fron nephrogenic systemic fibrosis patients: release of free Gd from genetic resonance imaging (MRI) contrast agents. Appl Surf Sci 2008; 255: 1181-4.
22. Thakral C, Abraham JL. Gadolinium-induced nephrogenic systemic fibrosis is associated with insoluble Gd deposits in Tissues: In vivo transmetallation confirmed by microanalysis. J Cutan Pathol 2009; 36: 1244-54.
23. Morcos SK, Thomsen HS. Nephrogenic systemic fibrosis: more questions and some answers. Nephron Clin Pract 2008; 110: c24-c32.
24. Morcos SK. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: Is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol 2007; 80: 73-6.
25. Idee J-M, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fund Clin Pharmacol 2006; 20: 563-76.
26. Schmitt-Willich H. Stability of linear and macrocyclic gadolinium based contrast agents. Br J Radiol 2007; 80: 581-2.
27. Port M, Idée JM, Medina C, Robic C, Sabatou M, Corot C. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals 2008; 21: 469-90.
28. Cacheris WP, Quay SC, Rocklage SM. The relationship between thermodynamics and toxicity of gadolinium complexes. J Magn Reson Imaging 1990; 8: 467-81.
29. Laurant S, Elst LV, Copoix F, Muller RN. Stability of MRI paramagnetic contrast media, a proton relaxometric protocol for transmetallation assessment. Invest Radiol 2001; 36: 115-22.
30. Laurant S, Elst LV, Copoix F, Muller RN. Comparative study of the physiochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging 2006; 1: 128-37.
31. Kimura J, Ishguchi T, Matsuda J, et al. Human comparative study of zinc and copper excretion via urine after administration of magnetic resonance imaging contrast agents. Radiat Med 2005; 23: 322-6.
32. 0C. Invest Radiol 2008; 43: 817-28.
33. Tweedle MF. Stability of gadolinium chelates, (letter to the Editor). Br J Radiol 2007; 80: 583-4.
34. Tweedle MF, Wedeking P, Kumar K. iodistribution of radiolabeled formulated gadopentetate, gadoteridol, gadoterate and gadodiamide in mice and rats. Invest Radiol 1995; 30: 372-80.
35. Pietsch H, Lengsfeld P, Jost G, Frenzel T, Hütter J, Sieber MA. Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents. Eur Radiol 2009; 19: 1417-24.
36. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998; 5: 491-502.
37. Thomsen HS. Is NSF only the tip of the "gadolinium toxicity" iceberg? J Magn Reson Imaging 2008; 28: 284-6.
38. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium (III) chelates and MRI agents: Structure, dynamics and applications. Chem Rev 1999; 99: 2293-352.
39. White GW, Gibby WA, Tweedle MF. Comparison of Gd (DTPA-BMA) (Omniscan) versus Gd (HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 2006; 41: 272-8.
40. Christoffersen J, Christoffersen MR, Kolthoff N, Bärenholdt O. Effects of strontium ions on growth and dissolution of hydroapatite and on bonde mineral detection. Bone 1997; 20: 47-54.
41. Murshima M, Drott HR, Carlow D, et al. Removal of gadolinium by peritoneal dialysis. Clin Nephrol 2008; 69: 368-73.
42. Perazella MA. Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link? Clin J Am Soc Nephrol 2007; 2: 200-2.
43. Cowper SE. Nephrogenic systemic fibrosis: a review and exploration of the role of gadolinium. Adv Dermatol 2007; 23: 131-54.
44. Cowper SE, Rabach M, Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol 2008; 66: 191-9.